Microcap Ledger Cue Biopharma, Inc. $CUE
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Somerville, MA
- Fiscal year end
- December 31
- Shares outstanding
- 7,264,414 [10-Q 2026-08-14]
What the company doesAI summary of filing
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics using its Immuno-STAT platform to selectively engage and modulate disease-specific T cells for treating autoimmune and inflammatory diseases, as well as oncology indications. The company has no approved products and generates no commercial revenue. Its pipeline includes CUE-401 for autoimmune diseases (preparing to file an IND application in the second quarter of 2026), the CUE-500 series for targeted cell depletion (CUE-501 licensed to Boehringer Ingelheim), and the CUE-100 series for oncology (CUE-101 and CUE-102 licensed to ImmunoScape). The company makes money through milestone payments and royalties from license agreements with collaborators and holds an exclusive worldwide license to core technology from Albert Einstein College of Medicine. [10-K 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $13.56M | −$158.25M | −$39.95M | $17.39M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $27.47M | −$26.60M | −$21.69M | $27.14M | [10-K 2026-03-16] |
| FY ended Dec 2024 | $9.29M | −$40.67M | −$36.33M | $22.46M | [10-K 2026-03-16] |
- Quarterly cash burn
- −$19.97M
- Cash runway Estimate
- ~2.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-10 | 63,350,327 | [10-Q 2024-11-14] |
| 2025-03-27 | 61,819,101 | [10-K 2025-03-31] |
| 2025-05-08 | 75,349,881 | [10-Q 2025-05-12] |
| 2025-08-08 | 76,845,904 | [10-Q 2025-08-12] |
| 2025-11-07 | 78,737,736 | [10-Q 2025-11-12] |
| 2026-03-13 | 97,660,791 | [10-K 2026-03-16] |
| 2026-05-12 | 4,045,701 | [10-Q 2026-05-14] |
| 2026-08-12 | 7,264,414 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-08-12; declared effective 2026-08-20 [S-3 2026-08-12]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-13 | Ray Sumita | exercise | 18,196 | — | [4 2026-08-17] |
| 2026-08-13 | Ray Sumita | sell | 2,383 | $29.37 | [4 2026-08-17] |
| 2026-08-13 | Ray Sumita | sell | 6,442 | $30.35 | [4 2026-08-17] |
| 2026-08-13 | Ray Sumita | sell | 4 | $31.13 | [4 2026-08-17] |
| 2026-08-13 | Meluzio Michael Vincent | exercise | 13,647 | — | [4 2026-08-17] |
| 2026-08-13 | Meluzio Michael Vincent | sell | 1,519 | $29.37 | [4 2026-08-17] |
| 2026-08-13 | Meluzio Michael Vincent | sell | 4,106 | $30.35 | [4 2026-08-17] |
| 2026-08-13 | Meluzio Michael Vincent | sell | 3 | $31.13 | [4 2026-08-17] |
| 2026-08-13 | Lin Shao-Lee | sell | 5,423 | $27.19 | [4 2026-08-14] |
| 2026-08-13 | Lin Shao-Lee | sell | 2,375 | $28.11 | [4 2026-08-14] |
| 2026-08-13 | Lin Shao-Lee | sell | 10,460 | $29.48 | [4 2026-08-14] |
| 2026-08-12 | Lin Shao-Lee | exercise | 109,179 | — | [4 2026-08-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-09-21 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-21 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | S-3 | Registration statement |
| 2026-08-03 | 8-K | Director or officer change |
| 2026-07-10 | 8-K | Material agreement entered; Unregistered sale of equity; Director or officer change |
| 2026-06-18 | S-3 | Registration statement |
| 2026-06-03 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-03 | S-3 | Registration statement |
Alerts for $CUE
Email me when Cue Biopharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.